Danaher makes lab instruments, diagnostic tools, and water-treatment systems—think of it as the hardware store for scientists and hospitals.
Money comes from selling instruments plus recurring consumables and services; gross margin is 58.51% and net margin 15.95%, with revenue at USD 24.57B in 2025.
Customers stick with Danaher's integrated systems because switching disrupts workflows; Thermo Fisher Scientific and Abbott compete, but the installed base and service lock-in are durable.
Sell (sector percentile 21) — value B-, growth B, profitability B, momentum C, revisions D. Updated daily, sector-relative, identical for every user.
Key events, in time order
Earnings released pre-market July 21, implied move ~±5%
None yet
None yet
Danaher is included in a watchlist of "Liquid Leader Stocks" based on price structure and trend analysis, suggesting a focus on technical indicators for potential trading opportunities.
Main discussion
📈Liquid Leader Stocks By Price Structure💧 Watchlist 👀 $LLY $DHR $NOW $SPOT $CVNA $SOFI $NFLX $CRCL Badges: 📅Earnings Yesterday/Countdown 📈Stage analysis 📉 ⚾️Strike Zone Font colors: 🟠Trend inflection ⬆️ ⚪️Trending ↗️ 🟢Buyable 🔵Reduce 50% if holding 🍐Restore full position if trimm
$MRNA is up almost 100% today Now its personalized cancer vaccine with Merck has succeeded in a Phase 3 melanoma trial. Genomics is quietly coming back to life Full research and ecosystem map: http://10xdisruptivestocks.substack.com/p/best-genomics-stocks Genomics Ecosystem: • DN
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
